These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 29535424)

  • 1. Comprehensive genomic profiling of neuroendocrine bladder cancer pinpoints molecular origin and potential therapeutics.
    Shen P; Jing Y; Zhang R; Cai MC; Ma P; Chen H; Zhuang G
    Oncogene; 2018 May; 37(22):3039-3044. PubMed ID: 29535424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Whole-exome mutational landscape of neuroendocrine carcinomas of the gallbladder.
    Liu F; Li Y; Ying D; Qiu S; He Y; Li M; Liu Y; Zhang Y; Zhu Q; Hu Y; Liu L; Li G; Pan W; Jin W; Mu J; Cao Y; Liu Y
    Signal Transduct Target Ther; 2021 Feb; 6(1):55. PubMed ID: 33563892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
    Manzano RG; Catalan-Latorre A; Brugarolas A
    BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer.
    Vandekerkhove G; Todenhöfer T; Annala M; Struss WJ; Wong A; Beja K; Ritch E; Brahmbhatt S; Volik SV; Hennenlotter J; Nykter M; Chi KN; North S; Stenzl A; Collins CC; Eigl BJ; Black PC; Wyatt AW
    Clin Cancer Res; 2017 Nov; 23(21):6487-6497. PubMed ID: 28760909
    [No Abstract]   [Full Text] [Related]  

  • 5. The genomic and transcriptomic landscape of metastastic urothelial cancer.
    Loriot Y; Kamal M; Syx L; Nicolle R; Dupain C; Menssouri N; Duquesne I; Lavaud P; Nicotra C; Ngocamus M; Lacroix L; Tselikas L; Crehange G; Friboulet L; Castel-Ajgal Z; Neuzillet Y; Borcoman E; Beuzeboc P; Marret G; Gutman T; Wong J; Radvanyi F; Dureau S; Scoazec JY; Servant N; Allory Y; Besse B; Andre F; Le Tourneau C; Massard C; Bieche I
    Nat Commun; 2024 Oct; 15(1):8603. PubMed ID: 39366934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological and genomic features in patients with head and neck neuroendocrine carcinoma.
    Ohmoto A; Sato Y; Asaka R; Fukuda N; Wang X; Urasaki T; Hayashi N; Sato Y; Nakano K; Yunokawa M; Ono M; Tomomatsu J; Toshiyasu T; Mitani H; Takeuchi K; Mori S; Takahashi S
    Mod Pathol; 2021 Nov; 34(11):1979-1989. PubMed ID: 34247193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of high-risk human papillomavirus and Rb/E2F pathway genomic alterations in mutually exclusive subsets of colorectal neuroendocrine carcinoma.
    Shamir ER; Devine WP; Pekmezci M; Umetsu SE; Krings G; Federman S; Cho SJ; Saunders TA; Jen KY; Bergsland E; Jones K; Kim GE; Kakar S; Chiu CY; Joseph NM
    Mod Pathol; 2019 Feb; 32(2):290-305. PubMed ID: 30237525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
    Hovelson DH; Udager AM; McDaniel AS; Grivas P; Palmbos P; Tamura S; Lazo de la Vega L; Palapattu G; Veeneman B; El-Sawy L; Sadis SE; Morgan TM; Montgomery JS; Weizer AZ; Day KC; Neamati N; Liebert M; Keller ET; Day ML; Mehra R; Tomlins SA
    Eur Urol; 2018 Dec; 74(6):741-753. PubMed ID: 30033047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma.
    Moss TJ; Qi Y; Xi L; Peng B; Kim TB; Ezzedine NE; Mosqueda ME; Guo CC; Czerniak BA; Ittmann M; Wheeler DA; Lerner SP; Matin SF
    Eur Urol; 2017 Oct; 72(4):641-649. PubMed ID: 28601352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biology and evolution of poorly differentiated neuroendocrine tumors.
    Rickman DS; Beltran H; Demichelis F; Rubin MA
    Nat Med; 2017 Jun; 23(6):1-10. PubMed ID: 28586335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma.
    Ross JS; Wang K; Gay LM; Al-Rohil RN; Nazeer T; Sheehan CE; Jennings TA; Otto GA; Donahue A; He J; Palmer G; Ali S; Nahas M; Young G; Labrecque E; Frampton G; Erlich R; Curran JA; Brennan K; Downing SR; Yelensky R; Lipson D; Hawryluk M; Miller VA; Stephens PJ
    Clin Cancer Res; 2014 Jan; 20(1):68-75. PubMed ID: 24192927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterizing the Genomic Landscape of the Micropapillary Subtype of Urothelial Carcinoma of the Bladder Harboring Activating Extracellular Mutations of ERBB2.
    Posada JM; Yakirevich E; Kamat AM; Sood A; Jacob JM; Bratslavsky G; Grivas P; Spiess PE; Li R; Necchi A; Mega AE; Golijanin DJ; Pavlick D; Huang RSP; Lin D; Danziger N; Sokol ES; Sivakumar S; Ross JS; Cheng L
    Mod Pathol; 2024 Mar; 37(3):100424. PubMed ID: 38219954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma.
    Hedegaard J; Lamy P; Nordentoft I; Algaba F; Høyer S; Ulhøi BP; Vang S; Reinert T; Hermann GG; Mogensen K; Thomsen MBH; Nielsen MM; Marquez M; Segersten U; Aine M; Höglund M; Birkenkamp-Demtröder K; Fristrup N; Borre M; Hartmann A; Stöhr R; Wach S; Keck B; Seitz AK; Nawroth R; Maurer T; Tulic C; Simic T; Junker K; Horstmann M; Harving N; Petersen AC; Calle ML; Steyerberg EW; Beukers W; van Kessel KEM; Jensen JB; Pedersen JS; Malmström PU; Malats N; Real FX; Zwarthoff EC; Ørntoft TF; Dyrskjøt L
    Cancer Cell; 2016 Jul; 30(1):27-42. PubMed ID: 27321955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RB1 Genetic Alterations in Estrogen Receptor-Positive Breast Carcinomas: Correlation With Neuroendocrine Differentiation.
    Schwartz CJ; Marra A; Selenica P; Gazzo A; Tan K; Ross D; Razavi P; Chandarlapaty S; Weigelt B; Reis-Filho JS; Brogi E; Pareja F; Wen HY
    Mod Pathol; 2024 Aug; 37(8):100541. PubMed ID: 38897452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urothelial Cancers with Small Cell Variant Histology Have Confirmed High Tumor Mutational Burden, Frequent TP53 and RB Mutations, and a Unique Gene Expression Profile.
    Hoffman-Censits J; Choi W; Pal S; Trabulsi E; Kelly WK; Hahn NM; McConkey D; Comperat E; Matoso A; Cussenot O; Cancel-Tassin G; Fong MHY; Ross J; Madison R; Ali S
    Eur Urol Oncol; 2021 Apr; 4(2):297-300. PubMed ID: 32061548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive analysis of mutational and clinicopathologic characteristics of poorly differentiated colorectal neuroendocrine carcinomas.
    Lee SM; Sung CO
    Sci Rep; 2021 Mar; 11(1):6203. PubMed ID: 33737597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene Expression Profiling of Lung Atypical Carcinoids and Large Cell Neuroendocrine Carcinomas Identifies Three Transcriptomic Subtypes with Specific Genomic Alterations.
    Simbolo M; Barbi S; Fassan M; Mafficini A; Ali G; Vicentini C; Sperandio N; Corbo V; Rusev B; Mastracci L; Grillo F; Pilotto S; Pelosi G; Pelliccioni S; Lawlor RT; Tortora G; Fontanini G; Volante M; Scarpa A; Bria E
    J Thorac Oncol; 2019 Sep; 14(9):1651-1661. PubMed ID: 31085341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of adult rhabdomyosarcoma and high-grade neuroendocrine carcinoma of the urinary bladder reveals novel PPP1R12A fusions in rhabdomyosarcoma.
    Gupta S; Sosa CP; Kosari F; Folpe A; Bhinge KN; Yang L; Agahi A; Johnson SH; Frank I; Boorjian SA; Hansel DE; Al-Ahmadie HA; Reuter VE; Vasmatzis G; Jimenez RE; Herrera-Hernandez L; Cheville JC
    Hum Pathol; 2019 Jun; 88():48-59. PubMed ID: 30946934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of new driver and passenger mutations within APOBEC-induced hotspot mutations in bladder cancer.
    Shi MJ; Meng XY; Fontugne J; Chen CL; Radvanyi F; Bernard-Pierrot I
    Genome Med; 2020 Sep; 12(1):85. PubMed ID: 32988402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A first case of ductal adenocarcinoma of the prostate having characteristics of neuroendocrine phenotype with PTEN, RB1 and TP53 alterations.
    Kobayashi H; Kosaka T; Nakamura K; Shojo K; Hongo H; Mikami S; Nishihara H; Oya M
    BMC Med Genomics; 2021 Oct; 14(1):245. PubMed ID: 34627261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.